Implications of Heterogeneity in Multiple Myeloma

Sanjay de Mel, Su Hong Lim, Moon Ley Tung, and Wee-Joo Chng

1 Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore
2 Cancer Science Institute of Singapore, National University of Singapore, Singapore
3 National University Health System, NUHS Tower Block, Level 7, 1E Lower Kent Ridge Road, Singapore 119228

Correspondence should be addressed to Wee-Joo Chng; wee.joo.chng@nuhs.edu.sg

Received 27 March 2014; Accepted 2 May 2014; Published 2 July 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Sanjay de Mel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Multiple myeloma is the second most common hematologic malignancy in the world. Despite improvement in outcome, the disease is still incurable for most patients. However, not all myeloma are the same. With the same treatment, some patients can have very long survival whereas others can have very short survival. This suggests that there is underlying heterogeneity in myeloma. Studies over the years have revealed multiple layers of heterogeneity. First, clinical parameters such as age and tumor burden could significantly affect outcome. At the genetic level, there are also significant heterogeneity ranging for chromosome numbers, genetic translocations, and genetic mutations. At the clonal level, there appears to be significant clonal heterogeneity with multiple clones coexisting in the same patient. At the cell differentiation level, there appears to be a hierarchy of clonally related cells that have different clonogenic potential and sensitivity to therapies. These levels of complexities present challenges in terms of treatment and prognostication as well as monitoring of treatment. However, if we can clearly delineate and dissect this heterogeneity, we may also be presented with unique opportunities for precision and personalized treatment of myeloma. Some proof of concepts of such approaches has been demonstrated.

1. Introduction

Multiple myeloma (MM) is the second most common hematologic malignancies in the world. It arises from clonal plasma cells that secrete monoclonal proteins that can be measured in the serum and urine for diagnosis and disease monitoring. The disease manifests through anemia, hypercalcaemia, renal impairment, and lytic bone lesions. Patients may present with bone fractures, renal failure, and hence significant morbidity [1]. All myelomas are probably preceded by a precursor asymptomatic state called monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM) [2, 3]. The progression to symptomatic disease is most likely through clonal evolution and acquisition of additional genetic events [4]. In recent years, a number of new treatments have been approved for myeloma, including thalidomide, bortezomib, lenalidomide, liposomal doxorubicin, carfilzombi, and pomalidomide. The increase in therapeutic options and the potency of these drugs have greatly improved the survival of patient who now survives for a median of 8 years from diagnosis [5]. Despite this progress, MM is still generally an incurable disease. Drug resistance and disease refractoriness are the common terminal pathways leading to death. A key factor underlying the clinical and therapeutic challenge is multiple layer of heterogeneity that exists in myeloma.

2. Molecular Heterogeneity

Studies over the years have shown that the MM genome is complex. However some of the genetic abnormalities cluster together which may suggest cooperating events. In addition, many abnormalities may affect similar pathways suggesting that there are key pathways affected in MM that may be important for disease pathogenesis and may represent good therapeutic targets.

2.1. Ploidy. At the chromosome level, myeloma can be broadly classified into hyperdiploid (48–74 chromosomes) and nonhyperdiploid myeloma. The hyperdiploid myeloma is characterized by a unique pattern of trisomies affecting many
of the odd-numbered chromosomes such as chromosomes 3, 5, 7, 9, 11, 15, 19, and 21 [6]. The hyperdiploid and nonhyperdiploid dichotomy is an early event in myeloma pathogenesis as these patterns can be detected at the MGUS stage [7]. The reasons that this unique pattern of trisomies is seen and what triggers the acquisition of these trisomies are currently unknown.

2.2. Chromosome Gains and Losses. A number of chromosomal gains and deletions are common in multiple myeloma. These include deletion of chromosome 13, deletion of chromosome 17p13, deletion of chromosome 1p, and gain of chromosome 1q21. Chromosome 13 deletion is an early event that is also present in a substantial proportion of MGUS. Chromosome 17p13 deletion, chromosome 1p deletion, and gain of chromosome 1q21 on the other hand are most likely secondary events associated with disease progression, as they are rarely detected in MGUS [8]. Importantly, the critical gene(s) located on these chromosomes that may be of functional importance is not yet known. For chromosome 13, we previously showed that minimal deleted regions contain RB1 and NBEA and hence may be the implicated genes in this region [9]. In addition, miRNAs that are located within this region may also be relevant [10]. However, there is as yet no functional study that confirms their relevance to myeloma biology.

For chromosome 1q, a number of genes, such as CKSIB [11], BCL9 [12], MCL1 [13], PDZKI [14], and MUC1 [15], have been implicated. However, it is still unclear whether one or more of these genes are relevant to myeloma biology. For chromosome 1p, we previously identified a region around 1p31-32, which is relevant for prognosis. Amongst the genes located within this locus, several have correlated expression with DNA copy number and may be functionally relevant, although there is no conclusive evidence so far [16]. For chromosome 17p13, the most likely candidate is TP53. TP53 is within the minimally deleted region on chromosome 17p13 [17]. Furthermore, using sequencing in isolated plasma cells, p53 was mutated in 37% of patients with 17p13 deletion and none in those without [18]. However, 17p loss is almost always monoallelic and p53 mutation does not occur in most patients with 17p13 deletion, while methylation of the TP53 promoter is relatively rare. This suggests that if p53 is the important gene, then it has to be acting in a haploinsufficient manner. We showed, using a panel of cell lines with different p53 abnormalities and using knockdown and overexpression studies, that the level of p53 affects its function and response to both genotoxic and nongenotoxic stress providing clear evidence that TP53 is a haploinsufficient tumor suppressor in MM (Teoh PJ et al. leukemia in press).

2.3. Translocations. These rearrangements juxtapose the strong promoters within the immunoglobulin heavy chain (IgH) gene locus to an oncogene and lead to very high expression of these oncoproteins. A number of recurrent translocations have been identified in myeloma dysregulating a few classes of proteins, namely, FGFR3/MMSET, Cyclin D (Cyclin D1 and Cyclin D3), and MAFs [8] (Table 1). These are thought to be primary translocations as they already exist at the MGUS stage and are probably initiating events. In gene expression studies, these translocations drive cognate expression signatures that are dominant and are easily identified in gene expression studies. Besides these recurrent translocations, the IgH locus is also involved in nonrecurrent or what is sometimes called secondary translocations involving unknown partners. These are so called because they are thought to represent secondary events that may be important in disease progression. MYC is another gene that is recurrently rearranged. It was initially described as the archetypical genes involved in complex rearrangement in myeloma as a secondary event in myeloma progression. It was subsequently found that translocation of MYC can be detected in about 15% of newly diagnosed patient [19]. More recently, it was shown that the MYC pathway is activated in majority of myeloma patients and may be an important transforming event from MGUS to MM [20]. Using high resolution tiling arrays around the MYC locus, it was found that rearrangements of MYC are also common in newly diagnose myeloma and most of these rearrangements affect enhancers and superenhancers of MYC causing an increase in MYC expression [21].

2.4. Mutations. RAS was one of the commonly mutated genes in MM, detected in 20–45% of newly diagnosed myeloma patients depending on study cohort and methods used for mutation detection [6]. Both N-RAS and K-RAS can be mutated, with different studies showing different frequency of mutations in these genes. In a large ECOG study, mutations in N-RAS (about 70% of all RAS mutations) are more common than in K-RAS (about 30% of all RAS mutations) [22]. On the other hand, a study from the University of Arkansas found that the frequencies of N- and K-RAS mutations are quite similar [23]. Recently, sequencing studies in 203 MM patients found that K-RAS and N-RAS mutations are found in 23% and 20%, respectively [24]. RAS mutation is rare in MGUS [25]. This suggests that it is a potential transforming genetic factor and may also be involved in disease progression. TP53, a well-known tumor suppressor gene, is also mutated in myeloma although it is not very common. A large ECOG study using conformation sensitive gel electrophoresis found TP53 mutated in 3% of cases [26]. More recently, mutation in TP53 was found in 9% of cases using whole exome or whole genome sequencing. The use of deep sequencing has resulted

### Table 1: Recurrent translocations involved in multiple myeloma.

| Translocations | Gene deregulated | Frequency |
|---------------|-----------------|-----------|
| t(4;14) (p16; q32) | MMSET, FGFR3 | 15% |
| t(11;14) (q13; q32) | CCND1 | 16% |
| t(6;14) (p21; q32) | CCND3 | 2% |
| t(12;14) (p13; q32) | CCND2 | <1% |
| t(14;16) (q32; q23) | MAF | 5% |
| t(14;20) (q32; q11) | MAFB | 2% |
| t(8;14) (q24; q32) | MAF | 1% |
Table 2: Genes affected by recurrent mutations in multiple myeloma.

| Gene    | Frequency (%) |
|---------|---------------|
| KRAS    | 23            |
| NRAS    | 20            |
| DIS3    | 11            |
| FAM46C  | 11            |
| TP53    | 8             |
| BRAF    | 6             |
| TRAF3   | 5             |
| PRDM1   | 5             |
| RBL1    | 3             |
| CYLD    | 2             |

in the identification of previously unknown genes that are recurrently mutated at a significant frequency in myeloma. These include DIS3, FAM46C, BRAF, TRAF3, PRDM1, and RBL1 (Table 2) [24].

2.5. Clustering. Amongst all these genetic chaos, some patterns and clustering around certain pathways exist. The recurrent primary translocations are predominantly seen in nonhyperdiploid myeloma. The primary events of translocations and hyperdiploidy seem to converge on the activation of one or more of the Cyclin D proteins [27].

Deletion 13 is also more common in nonhyperdiploid myeloma [28]. However, MYC rearrangements and activation occur more commonly in hyperdiploid myeloma. As MYC activation and chromosome 13 deletion are considered early events likely to play a role in disease transformation from MGUS to MM, it suggests that different genetic subtypes of myeloma may have different requirements for transformation. RAS mutations are not enriched according to ploidy but are significantly more common in tumors overexpressing Cyclin D1. More recent studies suggest that DIS3 mutations are significantly associated with nonhyperdiploid myeloma [24]. This suggests that there are specific combinations of genetic abnormalities that may collaborate during disease progression. On the other hand, secondary events such as IgH translocations involving unknown partners as well as chromosome 1 abnormalities and chromosome 17p13 deletions are distributed similarly across the main genetic subtypes.

Besides disease developmental pathways where there appears to be some preferential combination of abnormalities, overall, there are some pathways that are recurrently deregulated by different mechanisms in myeloma. The NFKB pathway is affected through mutations, deletions, and amplifications of different genes including CYLD, TRAF3, TRAF2, and NFKB1A [24, 29, 30]. Cell cycle related genes are also commonly affected including CCND1, CCND2, CCND3, RBL1, p16, and p18 [4, 23, 24]. Another commonly affected signaling pathway is the RAS-MAPK pathway with N-RAS, K-RAS, and BRAF recurrently mutated [24, 31]. Histone modifying enzymes, coagulation cascades, and the telomerase related pathways are also commonly affected (Table 3) [24, 31].

2.6. Clinical Implication. The clinical impact of these different genetic and molecular abnormalities is 3-fold. One, the different abnormalities have different prognostic relevance. Studies have consistently shown that deletion of 17p13 and the (4;14) translocation whether detected by FISH or cytogenetics is an independent bad prognostic factor, although the adverse effect of t(4; 14) can be partially abrogated by velcade-based treatment [8, 32, 33]. Other abnormalities such as 1p21 amplification [34–36] and t(14; 16) [37–39] have also been commonly associated with poor outcome although this is not observed in every study. More recently a number of studies has shown that lp deletion is independently and significantly associated with shorter survival, confirming earlier data from cytogenetic analysis [16, 40, 41]. Two, an understanding of the potential driving mutations in myeloma could lead to opportunities for precision medicine and targeted therapy. The recent description of a relapse patient with BRAF mutation responding spectacularly to BRAF inhibitor is one such proof of concept example [42]. It is therefore critical to identify driver mutations and pathways in myeloma so that patients can be matched to the most appropriate treatment. In this regard, treatment targeting the recurrently affect and functionally important pathway would be an important way forward. The cell cycle pathway, NFKB and RAS-MAPK pathways, would be good starting point. Third, some of these genetic mutations are predictors of response to drugs. In particular NFKB mutations, especially TRAF3 mutation, are associated with better response and progression free survival with bortezomib treatment [29]. More recently, mutation of NRAS but not KRAS has been shown to reduce myeloma sensitivity to bortezomib therapy [43].

3. Clinical Heterogeneity

3.1. Important Determinant of Outcomes. The variable outcome of patients with the same therapy suggests that there is underlying clinical heterogeneity. While some of this can be explained by the underlying biology of the tumor as described in the sections above, other factors such as host factors and extent of disease involvement are also important.

Age is an important prognostic factor. It impacts on the ability of patient to tolerate treatment and cope with disease complications. A large global study showed that there is progressive shortening of survival with increasing age even in patients treated with novel agents [44]. Conversely, a young age is an important independent factor associated with very long outcome [45].

A number of factors that may reflect underlying disease burden have been developed. The Durie-Salmon staging system combines a number of factors including renal function and number of bone lesions [46]. However, the system is cumbersome and lacks sensitivity. It has since been superseded by the International Staging System which is made up of 2 factors, beta-2 microglobulin, which reflects disease activity, and albumin, which reflects host fitness. The ISS is robustly derived and validated in large global cohorts and is easy to apply. These 2 factors emerged as the most significant and independent prognostic factors, trumping
### Table 3: Pathways commonly affected by mutations.

| Pathway                                                                 | Mutated genes                                                                                                                                                                                                |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cell cycle pathway including G1-S phase transition and checkpoints     | CCNA1, CCNB1, CCND1, CDK4, CDK6, CDK7, CDKN1B, CDKN2A, CDKN2C, RBL1, CDK4, PRB1, ABL1, ATM, ATR, CDK6, SKP2, TGFB1, TGFB2, TGFB3                                                                                   |
| TERT pathway                                                           | MAX, MYC, SPI, SP3, WT1                                                                                                                                                                                      |
| p38 MAPK pathway                                                       | ATF2, DAXX, GRB2, HMGN1, MAP2K6, MAP3K7, MAP3K9, MAPK4, MAX, MEF2A, MEF2D, MKN1, MYC, PLA2G4A, RAC1, RIPK1, RPS6KA5, SHCI, TGFB1, TGFB2, TGFB3, TRAF2                                                                 |
| Histone methyltransferase                                              | KDM6A, MLL, MLL2, MLL3, NSD1, WHSCI, WHSCIL1                                                                                                                                                                |
| NFKB pathway                                                           | BIRC2, BIRC3, BTRC, CARD16, CARD12, CARD6, CARD8, CYLD, FBXW11, IKBIP, IKBKAP, IKBKB, IKBKE, IL1R1, IRAK1, MAP3K4, MAP3K7, MYD88, NFKB2, NFKBIB, NOD2, RELA, RIPK1, RIPK2, RIPK4, TLR4, TRAF2, TRAF3, TRAF3IPI |
| Clotting pathway                                                       | COL4A1, COL4A2, COL4A3, COL4A5, COL4A6, F11, F3, F5, F7, F8, FGA, FGG, TFPi                                                                                                                                   |

### Table 4: GEP-based prognostic signatures.

| GEP signature              | Methods                                                                                                                                                                                                 |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| UAMS 70-gene [49]          | Derived by comparing expression of profiles of patients with top and bottom quartile of survival treated on total therapy II                                                                           |
| IFM signature [50]         | Derived by comparing expression of profiles of patients with good and poor outcome in IFM trials                                                                                                |
| Centrosome index [51]      | Based on expression of constituents of the centrosome                                                                                                                                                |
| HZD cell death signature [52] | Signature derived from genes homozygously deleted in myeloma as detected by array comparative genomic hybridization                                 |
| IL6-HMCL signature [53]    | 13-gene signature from genes induced upon IL6 stimulation of human myeloma cells lines                                                                                                               |
| Proliferation index [54]   | Curated signature based on proliferation genes                                                                                                                                                         |
| EMC 92-gene signature [55] | 92-gene signature based on differentially expressed genes between patient with good and poor outcome on HOVON trial                                                                               |
| Chromosome instability genomic event count (CINGEC) signature [56]    | Based on differentially expressed genes between patients with the top and bottom quartile of genomic instability score based on number of genetic abnormalities identified by array comparative genomic hybridization |

more traditional prognostic factors such as blood counts, m-protein levels, bone marrow plasma cell involvement, renal function, calcium level, and the types of immunoglobulin [47]. The incorporation of ISS with high-risk genetics provides further refinement to the prognostic system [48].

Can we further refine this dissection of clinical heterogeneity to more accurately segregate patients with different response to treatment and outcome? Gene expression profiles are very strong predictors of outcome. There are a number of signatures that are independently associated with poor outcome (Table 4). However, the confusion surrounds which one is best, how best to use them, and why they hardly share any individual genes. We undertook a meta-analysis to look at these signatures individually and in combination to set up a framework for applying gene expression signature for the prognosis of patients in the clinical setting. We found that combinations of signatures are more powerful predictors of outcome than any individual signature and we develop a package, which will be available to all investigators to apply to their own data for real-time prospective validation (Chung TH et al. in press).

The next challenge will be to assess this GEP signature in combination with ISS and high-risk genetics in an international exercise along the lines of ISS to hopefully arrive at a unified prognostic system.

### 3.2. Therapeutic Implications.

The ability to carefully dissect the risk of patients in relation to the different treatment regimen and strategy is important. While the path towards precision medicine in myeloma will be a long process as we have to develop the treatment to match to patients’ different mutations and also importantly identify the critical mutations to target, what we already have now are very effective treatments that have benefitted a large number of patients. How best to use the current treatment in terms of optimizing benefit while minimizing unnecessary treatment and toxicity is therefore a highly relevant clinical questions. Based on currently available prognostic factors, patients can be stratified into 3 risk groups. While at present, there is no evidence that different treatment should be recommended for the different risk groups, it will be important for risk stratification to be incorporated into future trial design to ensure that we can optimize treatment according to risk groups [57].

### 4. Clonal Heterogeneity

Data from next generation sequencing studies has challenged the traditional dogma that clonal evolution in cancer occurs in a linear fashion through stepwise accumulation of mutations. Numerous studies now propose a branching pattern of
clonal evolution in keeping with Darwinian principles [58]. In myeloma it is no different. Furthermore, these studies suggest related clones with different composition of genetic abnormalities coexist.

4.1. Evidence for Clonal Heterogeneity and Evolution in MM. Recent studies using single nucleotide polymorphism (SNP) arrays and whole exome sequencing [59], array comparative genomic hybridization (aCGH) [60], and whole genome sequencing (WGS) [61] have clearly demonstrated the presence of multiple clonally related tumor cell populations within the same patient that has different composite of genetic aberrations.

In a clinical study using SNP arrays and whole exome sequencing on 67 MM patients, the percentage of subclonal mutations in each patient varied from 10% to 80% [59]. In a study using WGS on bone marrow samples obtained from a patient with MM at serial time points from diagnosis to demise, 15 mutations were found to be present at all time points, representing the mutational profile of the common ancestor clone. The samples taken at each relapse had unique mutations, some of which disappeared at the first relapse and returned at subsequent relapse [61]. These findings strongly support the hypothesis that clonal evolution occurred in this patient and contributed to her disease progression; it also raises the possibility of alternating clonal dominance that may be selected under treatment pressure.

Using aCGH in 28 patients with serial samples, Keats et al. identified three patterns of clonal evolution among the patients: loss of copy number abnormalities (CNA), gain of CNA, and both losses and gains of CAN, with increasing number of CNAs as the disease progress. There is also an association between increase CAN and high-risk genetic abnormalities. In a patient whom they have material to study in depth, they were able to identify four clones that showed alternating dominance at different time points. In addition, specific clones were selected for by proteasome inhibitor treatment and melphalan. Clonal dominance and selection by treatment is further demonstrated using a mouse model of myeloma [60].

4.2. Mechanisms of Clonal Evolution. Clonal evolution occurs due to driver mutations or larger scale genomic crises, which can be stimulated by tumour, host, environmental, and treatment-related factors. A number of driver mutations have been implicated in the clonal evolution of MM (Table 5). Chromothripsis is an example of a genomic crisis, which is characterized by spontaneous catastrophic chromosome breakage followed by reassembly resulting in significant loss of chromosomal material [62]. Features of chromothripsis were detected in 1.3% of patients in a study of 764 patients with newly diagnosed MM. Of the 10 patients with chromothripsis, five relapsed within one year and three died during that period [63]. This study suggests that chromothripsis is associated with rapid clinical progression and a poor prognosis that needs to be validated in further studies.

It has recently been shown by whole exome sequencing that clonal heterogeneity is also present at the asymptomatic MGUS and SMM stages. The investigators went on to demonstrate that the majority of subclones present at the MM stage are already present at the SMM stage. Genetic lesions that may trigger the transformation from SMM to MM were identified [64] (Table 5).

4.3. Clinical Implications of Clonal Heterogeneity. The emerging concept of clonal heterogeneity and alternating clonal dominance in myeloma has clear therapeutic implications. In the patient studied by Keats et al., the dominant clone detected during her first relapse had mutations leading to NFkB activation, this clone was effectively treated with carfilzomib. At her second relapse however the dominant clone was associated with a different mutational profile and she had an inferior response to bortezomib [60]. These findings suggest that we should have an understanding of the clonal composition of the tumor at each treatment phase and use this information to guide treatment. The challenge is to identify treatment modalities and combinations effective against the main functionally relevant genetic abnormalities in MM. While the current treatment armamentarium is expanding, it is still limited to a few classes of drugs. We need to expand this portfolio in a systematic manner to match treatment with mutational profiles. The use of patient-derived xenograft models and faithful myeloma mouse models such as the V-K-MYC model [65] and the availability of an increasingly broad range of novel therapeutics should facilitate the generation of this knowledge.
5. Cellular Differentiation Heterogeneity

Evidence is emerging that the clonal cells that constitute myeloma are not homogeneously of mature plasma cell phenotype. In fact, a hierarchy of precursor cells with different clonogenic potential, different gene expression, phenotype, and sensitivity to therapy may exist. Sitting at the apex of this hierarchy of clonally related cellular population is the putative clonogenic myeloma progenitor cells (MPC).

5.1. Evidence for the Existence of MPC. MM plasma cells are quiescent and have a low proliferative index. As a result, its tumorigenic potential and ability has been questioned [66]. It is therefore postulated that a precursor population might be responsible for disease initiation.

Early work by Hamburger and colleagues showed that bone marrow cells from MM patients were capable of in vitro colony formation [67]. Bakkus and coworkers later identified a population of mature B-cells in the peripheral blood and marrow of MM patients that were clonally related to MM plasma cells and hence postulated to be MPCs [68]. In a separate report, a patient with MM, who went on to developed B lymphoblastic leukaemia, has B lymphoblasts that share similar clonal immunoglobulin gene rearrangement as the malignant PCs detected at diagnosis. The leukaemic B-cells when grafted into NOD/SCID mice led to the development of lytic bone lesions. The B-cells identified in the bone marrow of these mice were CD45+, CD19+, CD20+, and CD138−. This study suggested that some of the circulating B-cells in the patient were MPCs capable of initiating MM in vivo [69].

More recently, Matsui et al. isolated CD138− mature B-cells from MM cell lines as well as clinical samples. This population had a greater capacity for colony formation in vitro and in vivo than CD138+ MM plasma cells and their expression of Ki 67 was greater [70]. They also showed that these MM forming mature B-cells had a CD19+, CD20+, and CD138− phenotype with light chain restriction, consistent with the phenotype of the putative MM clonogenic cells identified in earlier studies [71].

The expression of aldehyde dehydrogenase (ALDH) is characteristic of cancer stem cells [72]. Using ALDH as a marker, Reghunathan and coworkers identified a CD138− population constituting 2.5% of cells in a human MM cell line. Indeed, 45% of the CD138− population expresses ALDH1 compared to less than 1% of the CD138+ cells. These CD138− ALDH+ cells had superior colony forming capacity both in vitro and in vivo. They also have similar gene expression profiles compared to hematopoietic stem cells (HSC) and leukaemic stem cells (LSC). These data further support the existence of a clonogenic population in the CD138− fraction of MM [73].

5.2. Hierarchical Organization of MPC. Clonally related sub-populations of MPCs, sharing common IgH gene rearrangement, have been detected in bone marrow of MM patients. Amongst these immunophenotypically distinct subpopulations, the CD19+CD138− cells had a superior colony forming capacity compared to the CD138+ population [75]. Chaidos and colleagues analyzed bone marrow samples from 10 MM patients and identified four clonally related subpopulations of MPC. Using a mathematical growth model they showed that differentiation occurred in the following sequence: memory B-cell followed by plasmablast followed by preplasma cell and finally plasma cell. Importantly, they demonstrated that the CD138− dim plasma cells were also capable of reverting back to a preplasma cell phenotype [76]. A hierarchical organization of clonally related MPCs was furtherly demonstrated by studying the expression of XBP-1, a transcription factor important for the differentiation of plasma blasts into plasma cells. In this study, five clonally related subpopulations of MPCs in bone marrow samples of MM patients were identified with XBP-1 expression universally negative in the CD38−CD138− populations [77].

These studies strongly suggest the presence of a clonal hierarchy of MPCs consisting of phenotypically distinct subsets with a defined maturation sequence (see Table 6).

5.3. Gene Expression Differs between MPC and Mature Plasma Cells. Several studies have compared the gene expression profile of CD138− to CD138+ clonal myeloma cells. In 2 of these studies [73, 76], the polycomb repressor complex 2 (PRC2) related genes, such as EZH2, EED, and SUZ12, were upregulated in the CD138− subsets. The PRC genes promote histone methylation and reduced expression of their targets. The overexpression of PRC2 genes and subsequent reduced expression of target genes such as the cyclin dependent kinase inhibitors (such as p21) would increase the proliferative capacity of the CD138− PCs. In one of these studies, other genes involved in epigenetic regulation of gene expression such as histone demethylases, histone acetyltransferases, and deacetylases also have altered expression. The resultant “epigenetic plasticity” may explain the bidirectional transition of MPCs observed in the study [76]. In another study, the RARA2 gene was found to be overexpressed in the CD138− subset. Overexpression of RARA2 resulted in the activation of the Wnt and Hedgehog pathways, increased expression of ALDH, expression of embryonic stem cell genes, and greater clonogenic potential in the MM cells. These effects were reversed upon silencing of RARA2 [78].

Two groups have also looked at the clinical relevance of gene expression signature derived from these clonogenic myeloma cells. Kassambara and colleagues focused on genes differentially expressed in clonogenic myeloma cells that are not related to proliferation or previous prognostic gene expression signatures. They identified 50 genes which were of prognostic significance in MM. Thirty-seven of these 50 genes were also found to be overexpressed in three human stem cell populations, pluripotent stem cells, hematopoietic stem cells, and mesenchymal stem cells. They went on to build a “stem cell score” based on the expression of these genes, which proved strongly prognostic in two independent patient cohorts [79]. In the study of Reghunathan and colleagues, the gene signature comprising genes differentially expressed in CD138− clonogenic population compared to the CD138+ population was associated with poorer outcome in stem cell transplant as well as velcade-treated MM patient
is relevant as studies have shown that the CD138 sampled, may be missed for MRD assessment. This limitation disease within the bone marrow, that is, not in the area samples. Therefore, disease outside the bone marrow or even disease within the bone marrow, that is, not in the area sampled, may be missed for MRD assessment. This limitation is relevant as studies have shown that the CD138– clonogenic MPCs have propensity for extramedullary sites [76]. This is where whole body imaging such as PET-CT may be useful in identifying extramedullary disease. However, the sensitivity of PET-CT in terms of MRD assessment is still unclear. Comparing FC and PCR, there is also subtle yet important difference in the population they may detect. FC-based MRD assessment is based on the detection of the aberrant phenotype of myeloma plasma cells and is therefore predominantly detecting the plasma cell component and hence will miss the clonogenic MPCs. PCR on the other hand detects the clonal rearrangements of IgH gene and therefore will identify any clonally related cells, including the MPCs (Figure 1). The predominant limitation of the PCR method is that clone specific rearrangements can only be identified in only less than 50% of cases in MM. This limitation may be overcome by using sequencing-based method to detect IgH gene rearrangement, which can be applied to more than 90% of cases (Martinez-Lopez et al. blood in press). Due to the challenge of cellular heterogeneity in MM, it is likely that more than 1 technique will need to be used for comprehensive MRD assessment in the future. Prospective study should be conducted to correlate PET-CT with FC and PCR/sequencing-based methods and to develop clinically useful algorithm for the application of these techniques possibly in a step-wise manner.

5.5. The Role of MPC in Drug Resistance and Disease Relapse. CD138– clonogenic MPCs have been shown by a number of groups to be more resistant to drugs used for myeloma treatment such as lenalidomide, dexamethasone, and bortezomib. This is in part due to the increased expression of ABCG2/BCRP drug transporter as well as higher levels of

| Study              | Gene                  | Differential expression | Function                                      |
|--------------------|-----------------------|-------------------------|-----------------------------------------------|
| Reghunathan et al. | PRC2 related (EZH2, EED, SUZ12) | Upregulated in CD 138− sub. | Via histone methylation, reduces the expression of p21 and other CDK inhibitors, driving proliferation. |
|                    | PRC1 related (BMI1)   | Upregulated in CD 138+ sub. | Promote differentiation of plasmablasts to mature plasma cells. |
|                    | BMP 2, BMP3, BMP4     | Upregulated in CD 138− sub. | Increased ALDH expression, increased activity of WNT and Hedgehog pathway signaling as well as Cyclin D1. |
| Yang et al. 2013   | RARα2                 | Upregulated in CD 138− sub. | Genes expressed in pluripotent stem cells. |
|                    | Oct 4, SOX 2, Nanog, Lin 28A | Upregulated in CD 138− sub. | |
ALDH [84]. The expression of these drug transporters may be induced by an increased expression of RARα2 [78]. More recently, through a series of elegant experiments, it was shown that in Velcade resistant patients, there is an increase in XBPI low expressing MPCs which share common genetic changes as the myeloma plasma cells. These cells produce less immunoglobulin and have less endoplasmic reticulum (ER) stress and express less unfolded protein response (UPR) genes and are therefore more resistant to velcade, which induce cell death in plasma cells with high immunoglobulin production and ER stress by inhibiting the UPR, which requires an active proteasome [77].

MPCs have also been shown to rely on survival and proliferation pathways used by stem cells. Peacock and colleagues demonstrated that CD138− CD19+ B-cells from MM cell lines and patient samples had constitutive activation of the Hedgehog (Hh) signaling pathway evident by the increased expression of the smoothened (SMO) protein [85]. It is possible that MPCs rely on these to avoid cell death induced by agents that are active against mature plasma cells.

5.6. Targeted Therapy against MPCs. Signaling pathways and other lesions unique to the clonogenic MPCs may form the basis for targeted therapy against MPCs. The histone deacetyltransferase inhibitor DZNep inhibits PRC2 and was shown to be more effective in killing CD138− compared to CD138+ MM cells [73]. Inhibition of Hh pathway signaling by cyclopamine was shown to reduce the clonogenic capacity of the CD138− CD19+ MPC fraction in two MM cell lines [85]. A phase I trial using another Hh pathway antagonist GDC-0449 (Vimodegib) in patients with high risk MM postautologous stem cell transplant has been completed and results are awaited. Blockade of the JAG-NOTCH interaction using NOTCH-Fc chimeric molecules resulted in impaired self-renewal capacity in MM cell lines [86]. Targeting the NOTCH pathway using the NOTCH inhibitor R0490927 in combination with melphalan has also been investigated in a phase II clinical trial for which the results are awaited. Based on the identification of high RARα2 expression in the CD138− MPC, Yang and coworkers showed that al-trans retinoic acid (ATRA) preferentially induced apoptosis in the CD138− fraction [78]. Telomerase activity is required for the survival of normal stem cells. Brennan and colleagues treated MM stem cells from cell lines and clinical samples with the telomerase inhibitor imetelstat. They found that telomerase inhibition resulted in inhibition of clonogenic growth as well as reduced expression of genes expressed by stem cells [87]. Clinical trials using telomerase inhibitors in MM are awaited. The long-term remissions achieved by selected MM patients who survive allogeneic stem cell transplant suggest the presence of a graft versus myeloma stem cell effect [88]. This has led to investigation of cellular therapy modalities targeting MPCs. Swift and colleagues demonstrated that the natural killer (NK) cell lines KHYG2 and NK-92 were selectively toxic to the MPC fraction in vitro [89]. Clinical trials using NK cells in MM are in progress. The concepts are still in early phase of clinical development and results from early phase clinical trials are still pending (Table 8).

6. Conclusion

Multiple levels of heterogeneity exist in MM, providing tremendous clinical challenges in diagnosis, prognosis, treatment, and monitoring. The understanding of biological relevance of the heterogeneity at the molecular, clonal, and cellular level and how these relate to clinical heterogeneity
Table 8: Summary of agents in development which may be selectively toxic to MPC.

| Drug/molecule                  | Mechanism of action                        | Phase/used in combination with other agents |
|--------------------------------|---------------------------------------------|---------------------------------------------|
| DZNep inhibitor                | Disruption of PRC2                          | Preclinical                                 |
| Vismodegib (GDC-0449)          | Hedgehog signaling inhibitor                | Phase I/after auto SCT                       |
| R0490927                       | NOTCH signaling inhibitor                   | Phase II/melphalan                           |
| MK571                          | MRP3 inhibitor                              | Preclinical/bortezomib                      |
| ATRA                           | Induces degradation of RARx2                | Preclinical                                 |
| Imetelstat                      | Telomerase Inhibitor                        | Preclinical                                 |
| NK cell therapy                | Cellular cytotoxicity                       | Preclinical                                 |

SCT = Stem cell transplant.

will provide important mechanistic insights that will guide future development of diagnostic, prognostic, therapeutic, and monitoring modalities to further personalize treatment, improve treatment precision, and lengthen the survival of MM patients.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] R. A. Kyle and S. V. Rajkumar, “Multiple myeloma,” Blood, vol. 111, no. 6, pp. 2962–2972, 2008.
[2] B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl, “A monoclonal gammopathy precedes multiple myeloma in most patients,” Blood, vol. 113, no. 22, pp. 5418–5422, 2009.
[3] O. Landgren, R. A. Kyle, R. M. Pfeiffer et al., “Monoclonal gammapathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study,” Blood, vol. 113, no. 22, pp. 5412–5417, 2009.
[4] G. J. Morgan, B. A. Walker, and F. E. Davies, “The genetic architecture of multiple myeloma,” Nature Reviews Cancer, vol. 12, no. 5, pp. 335–348, 2012.
[5] E. M. Ocio, P. G. Richardson, S. V. Rajkumar et al., “New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG),” Leukemia, vol. 28, pp. 525–542, 2014.
[6] R. Fonseca, B. Barlogie, R. Bataille et al., “Genetics and cytogenetics of multiple myeloma: a workshop report,” Cancer Research, vol. 64, no. 4, pp. 1546–1558, 2004.
[7] W. J. Chng, S. A. van Wier, G. J. Ahmann et al., “A validated FISH trisomy index demonstrates the hyperdiploid and non-hyperdiploid dichotomy in MGUS,” Blood, vol. 106, no. 6, pp. 2156–2161, 2005.
[8] R. Fonseca, P. L. Bergsagel, J. Drach et al., “International Myeloma Working Group molecular classification of multiple myeloma: spotlight review,” Leukemia, vol. 23, no. 12, pp. 2210–2221, 2009.
[9] J. O’Neal, F. Gao, A. Hassan et al., “Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma,” Experimental Hematology, vol. 37, no. 2, pp. 234–244, 2009.
[10] A. M. Roccaro, A. Sacco, B. Thompson et al., “MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma,” Blood, vol. 113, no. 26, pp. 6669–6680, 2009.
[11] E. Zhan, J. Sawyer, and S. Gupta, “Elevated expression of CKS1B at 1q21 is highly correlated with short survival in myeloma,” Blood, vol. 104, abstract 77, 2004.
[12] T. G. Willis, I. R. Zalcberg, L. J. A. Coignet et al., “Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21,” Blood, vol. 91, no. 6, pp. 1873–1881, 1998.
[13] R. W. Craig, E. W. Jabs, P. Zhou et al., “Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease,” Genomics, vol. 23, no. 2, pp. 457–463, 1994.
[14] J. Inoue, T. Otsuki, A. Hirasawa et al., “Overexpression of PDZK1 within the 1q42-1q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma,” American Journal of Pathology, vol. 165, no. 1, pp. 71–81, 2004.
[15] V. G. Dyomin, N. Palanisamy, K. O. Lloyd et al., “MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets,” Blood, vol. 95, no. 8, pp. 2666–2671, 2000.
[16] W. J. Chng, M. A. Gertz, T.-H. Chien et al., “Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma,” Leukemia, vol. 24, no. 4, pp. 833–842, 2010.
[17] K. D. Boyd, F. M. Ross, W. J. Tapper et al., “The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy,” Genes Chromosomes and Cancer, vol. 50, no. 10, pp. 765–774, 2011.
[18] L. Lodé, M. Eveillard, V. Trichet et al., “Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma,” Haematologica, vol. 95, no. 11, pp. 1973–1976, 2010.
[19] H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.-L. Harousseau, and R. Bataille, “Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors,” Blood, vol. 98, no. 10, pp. 3082–3086, 2001.
[20] W.-J. Chng, G. F. Huang, T. H. Chung et al., “Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma,” Leukemia, vol. 25, no. 6, pp. 1026–1035, 2011.
[21] M. Affer, M. Chesi, and W. D. Chen, “Promiscuous rearrangements of the MYC locus hijack enhancers and super-enhancers...
to dysregulate MYC expression in multiple myeloma,” \textit{Leukemia}, 2014.

[22] W. J. Chng, N. Gonzalez-Paz, T. Price-Troska et al., “Clinical and biological significance of RAS mutations in multiple myeloma,” \textit{Leukemia}, vol. 22, no. 12, pp. 2280–2284, 2008.

[23] W. J. Chng, O. Glebov, P. L. Bergsagel, and W. M. Kuehl, “Genetic events in the pathogenesis of multiple myeloma,” \textit{Best Practice and Research: Clinical Haematology}, vol. 20, no. 4, pp. 571–596, 2007.

[24] J. G. Lohr, P. Stojanov, S. L. Carter et al., “Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy,” \textit{Cancer Cell}, vol. 25, pp. 91–101, 2014.

[25] T. Rasmussen, M. Kuehl, M. Lodahl, H. E. Johnsen, and I. M. S. Dahl, “Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors,” \textit{Blood}, vol. 105, no. 1, pp. 317–323, 2005.

[26] W. J. Chng, T. Price-Troska, N. Gonzalez-Paz et al., “Clinical significance of TP53 mutation in myeloma [13],” \textit{Leukemia}, vol. 21, no. 3, pp. 582–584, 2007.

[27] P. L. Bergsagel, W. M. Kuehl, F. Zhan, J. Sawyer, B. Barlogie, and J. Shaughnessy Jr., “Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma,” \textit{Blood}, vol. 106, no. 1, pp. 296–303, 2005.

[28] R. Fonseca, C. S. Debas-Marun, E. B. Picken et al., “The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma,” \textit{Blood}, vol. 102, no. 7, pp. 2562–2567, 2003.

[29] J. J. Keats, R. Fonseca, M. Chesi et al., “Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma,” \textit{Cancer Cell}, vol. 12, no. 2, pp. 131–144, 2007.

[30] C. M. Annunziata, R. E. Davis, Y. Demchenko et al., “Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma,” \textit{Cancer Cell}, vol. 12, no. 2, pp. 115–130, 2007.

[31] M. A. Chapman, M. S. Lawrence, J. J. Keats et al., “Initial genome sequencing and analysis of multiple myeloma,” \textit{Nature}, vol. 471, no. 7339, pp. 467–472, 2011.

[32] N. C. Munshi, K. C. Anderson, P. L. Bergsagel et al., “Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2,” \textit{Blood}, vol. 117, no. 18, pp. 4696–4700, 2011.

[33] H. Avet-Loiseau, “Role of genetics in prognostication in myeloma,” \textit{Best Practice and Research: Clinical Haematology}, vol. 20, no. 4, pp. 625–635, 2007.

[34] I. Hanamura, J. P. Stewart, Y. Huang et al., “Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation,” \textit{Blood}, vol. 108, no. 5, pp. 1724–1732, 2006.

[35] R. Fonseca, S. A. van Wier, W. J. Chng et al., “Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma,” \textit{Leukemia}, vol. 20, no. 11, pp. 2034–2040, 2006.

[36] H. Avet-Loiseau, M. Attal, P. Moreau et al., “Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome,” \textit{Blood}, vol. 109, no. 8, pp. 3489–3495, 2007.

[37] H. Avet-Loiseau, F. Malard, L. Campion et al., “Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?” \textit{Blood}, vol. 117, no. 6, pp. 2009–2011, 2011.

[38] K. D. Boyd, F. M. Ross, L. Chiecchio et al., “A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial,” \textit{Leukemia}, vol. 26, no. 2, pp. 349–355, 2012.

[39] R. Fonseca, E. Blood, M. Rue et al., “Clinical and biologic implications of recurrent genomic aberrations in myeloma,” \textit{Blood}, vol. 101, no. 11, pp. 4569–4575, 2003.

[40] B. Hebraud, X. Leleu, V. Lauwers-Cancs et al., “Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients,” \textit{Leukemia}, vol. 28, pp. 675–679, 2014.

[41] M. Andrulis, N. Lehners, D. Capper et al., “Targeting the BRAF V600E mutation in multiple myeloma,” \textit{Cancer Discovery}, vol. 3, no. 8, pp. 862–869, 2013.

[42] G. Mulligan, D. I. Lichter, A. di Bacco et al., “Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy,” \textit{Blood}, vol. 123, pp. 632–639, 2014.

[43] H. Ludwig, V. Bolejack, J. Crowley et al., “Survival and years of life lost in different age cohorts of patients with multiple myeloma,” \textit{Journal of Clinical Oncology}, vol. 28, no. 9, pp. 1599–1605, 2010.

[44] H. Avet-Loiseau, M. Attal, L. Campion et al., “Long-term analysis of the ICM 99 trials for myeloma: cytogenetic abnormalities \{t(4;14), del(17p), 1q gains\} play a major role in defining long-term survival,” \textit{Journal of Clinical Oncology}, vol. 30, no. 16, pp. 1949–1952, 2012.

[45] B. G. M. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival,” \textit{Cancer}, vol. 36, no. 3, pp. 842–854, 1975.

[46] P. R. Greipp, J. S. Miguel, B. G. M. Dune et al., “International staging system for multiple myeloma,” \textit{Journal of Clinical Oncology}, vol. 23, no. 15, pp. 3412–3420, 2005.

[47] H. Avet-Loiseau, B. G. M. Durie, M. Cavo et al., “Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project,” \textit{Leukemia}, vol. 27, no. 3, pp. 711–717, 2013.

[48] J. D. Shaughnessy Jr. and B. Barlogie, “Using genomics to identify high-risk myeloma after autologous stem cell transplantation,” \textit{Blood and Marrow Transplantation}, vol. 12, no. 1, pp. 77–80, 2006.

[49] O. Decaux, L. Lodé, F. Magrangeras et al., “Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome,” \textit{Journal of Clinical Oncology}, vol. 26, no. 29, pp. 4798–4805, 2008.
patients treated with up-front autologous transplantation,” *Blood*, vol. 118, no. 23, pp. 5989–5995, 2011.

[84] W. Matsui, Q. Wang, J. P. Barber et al., “Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance,” *Cancer Research*, vol. 68, no. 1, pp. 190–197, 2008.

[85] C. D. Peacock, Q. Wang, G. S. Gesell et al., “Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 10, pp. 4048–4053, 2007.

[86] D. Chiron, S. Maiga, G. Descamps et al., “Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells,” *Blood Cells, Molecules, and Diseases*, vol. 48, no. 4, pp. 247–253, 2012.

[87] S. K. Brennan, Q. Wang, R. Tessler et al., “Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent Mechanisms,” *PLoS ONE*, vol. 5, no. 9, Article ID e12487, 2010.

[88] B. Björkstrand, P. Ljungman, H. Svensson et al., “Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation,” *Blood*, vol. 88, no. 12, pp. 4711–4718, 1996.

[89] B. E. Swift, B. A. Williams, Y. Kosaka et al., “Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model,” *Haematologica*, vol. 97, no. 7, pp. 1020–1028, 2012.